Related Experiment Video
Updated: May 16, 2026

Robot Assisted Distal Pancreatectomy with Celiac Axis Resection (DP-CAR) for Pancreatic Cancer: Surgical Planning and Technique
Published on: August 14, 2021
CAR's made it to the pancreas
Markus Chmielewski1, Amit Maliar, Zelig Eshhar
1Center for Molecular Medicine Cologne (CMMC); Department I of Internal Medicine; University Hospital Cologne; Cologne, Germany.
Engineered T cells targeting carcinoembryonic antigen (CEA) and ERBB2 showed therapeutic efficacy against pancreatic cancer. Targeting CD24, a cancer stem cell antigen, was also effective in preclinical models.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Stem Cells
Background:
- Pancreatic adenocarcinoma has a poor prognosis despite current treatments.
- Novel therapeutic strategies are urgently needed for pancreatic cancer.
- Chimeric antigen receptor (CAR) T cell therapy shows promise in oncology.
Purpose of the Study:
- To evaluate the efficacy of adoptively transferred T cells engineered with a chimeric antigen receptor (CAR) targeting CEA and ERBB2 in pancreatic cancer models.
- To investigate the therapeutic potential of targeting CD24, a cancer stem cell antigen, in pancreatic cancer.
Main Methods:
- Utilized clinically relevant preclinical models of pancreatic adenocarcinoma.
- Engineered T cells with a CAR specific for carcinoembryonic antigen (CEA) and ERBB2.
- Administered adoptively transferred engineered T cells as therapy.
- Investigated the efficacy of targeting CD24, a putative cancer stem cell antigen.
Main Results:
- Adoptively transferred T cells engineered with a CEA- and ERBB2-specific CAR demonstrated therapeutic efficacy against pancreatic carcinoma.
- Targeting CD24, a cancer stem cell antigen expressed on a subset of tumor cells, also proved effective.
- These findings highlight the potential of CAR T cell therapy in pancreatic cancer.
Conclusions:
- CAR T cell therapy targeting CEA and ERBB2 is a viable therapeutic strategy for pancreatic adenocarcinoma.
- Targeting cancer stem cell antigens like CD24 offers an alternative or complementary approach for pancreatic cancer treatment.
- Further research into engineered T cell therapies is warranted for improving pancreatic cancer outcomes.
Related Concept Videos
Pancreas
The broad head of the pancreas lies within the loop formed by the duodenum, while its slender body reaches towards the spleen. The tail of the pancreas is short and...
Cells and Secretions of the Pancreas
Exocrine function is carried out by acinar cells, organized into clusters known as acini. These cells contribute to digestion by releasing substantial quantities of enzyme-rich, alkaline digestive juices.
Concurrently, the dispersed clusters of endocrine cells throughout the...
Acute Pancreatitis I: Introduction
Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
Acute Pancreatitis II: Pathophysiology
Chronic Pancreatitis II: Pathophysiology

